Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics

This study is examining how kidney function and race/ethnicity affect the way the body processes treosulfan, a chemotherapy drug used as part of the preparation regimen before a stem cell transplant (allogeneic HSCT) in people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). **You may be eligible if...** - You are 18–80 years old with AML or MDS who qualifies for treosulfan-based conditioning before a stem cell transplant - You have a suitable donor (matched, haploidentical, or partially matched) - Your kidney function is at least moderately functional (creatinine clearance ≥30 mL/min) - Your Karnofsky performance score is 60% or higher - You agree to use effective contraception if applicable **You may NOT be eligible if...** - You have severe kidney failure (creatinine clearance below 30 mL/min) - You do not have an available donor - You do not qualify for a stem cell transplant by your medical team's assessment Talk to your doctor to see if this trial is right for you.